Advertisement

POSB357 Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

      Objectives

      Despite impaired quality of life, limited studies have evaluated health utility among patients with newly diagnosed acute myeloid leukemia (ND-AML) who are ineligible for intensive chemotherapy. The Viale-A and Viale-C studies are the only trials that collected EuroQoL 5-Dimension (EQ-5D) data for patients in different health states. The study aims to estimate the health state utility values among this population across multiple countries.

      Methods

      EQ-5D utility scores were estimated based on the pooled data from all patients with a baseline and post-baseline assessment in Viale-A and/or C trials. The utility scores were calculated using published country-specific value sets in the United Kingdom (UK), France, Canada, Sweden, Germany, Denmark, China, and South Korea. Three health states were assessed, event-free survival (EFS) with complete remission/complete remission with incomplete blood count recovery (CR/CRi), EFS without CR/CRi, and progressive/relapsed disease (PD/RL). The utility values (range: 0 [death] - 1 [best/perfect health state]) for these health states were estimated via a linear mixed-effects model to account for the correlations among repeated assessments for the same patient. The model also adjusted for grade 3/4 adverse events.

      Results

      The analysis included 390 and 186 patients from Viale-A and Viale-C, respectively. For the UK, the utility value based on the pooled trial data was 0.747 (standard error [SE] = 0.013) for EFS with CR/CRi, 0.725 (SE = 0.014) for EFS without CR/CRi, and 0.628 (SE = 0.017) for PD/RL. For other countries, the utility values ranged from 0.693 to 0.897 for EFS with CR/CRi, from 0.657 to 0.857 for EFS without CR/CRi, and from 0.569 to 0.793 for PD/RL.

      Conclusions

      EFS with CR/CRi was associated with the highest utility scores, followed by EFS without CR/CRi and PD/RL for ND-AML patients who are ineligible for intensive chemotherapy in all countries.